Created with Sketch.
The Readout Loud
32 minutes | 16 hours ago
Episode 149: Nancy Goodman on Covid vaccines for kids, & Greg Zuckerman on Novavax's remarkable rise
First, pediatric cancer advocate Nancy Goodman joins us to discuss why she believes Covid-19 vaccine trials need to be sped up for teens and children. Then, Wall Street Journal reporter Greg Zuckerman calls in to explain the unlikely story behind Novavax, a former biotech penny stock now on the verge of making history. Finally, we embark on a lightning round, featuring quick takes on the confirmation process for a new health secretary and the future of therapeutic stool.
36 minutes | 8 days ago
Episode 148: Akshay Sharma on gene therapy's setback, biotech's brashest VCs, & the FDA's future
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we break down a significant setback for Bluebird Bio’s gene therapy program with some help from Akshay Sharma, a bone marrow transplant expert at St. Jude Children’s Research Hospital. Then, STAT's Kate Sheridan joins us to discuss her deep dive into Flagship Pioneering, the superlatively successful and frequently grandiose venture firm behind Moderna. Finally, we dig into what the future might hold for a post-Trump FDA, which remains without a permanent commissioner.
35 minutes | 15 days ago
Episode 147: David Fajgenbaum on Covid-19 drugs, the state of the pandemic, & meme biotech stocks
When will we have enough vaccine doses? How many effective Covid-19 drugs are just waiting to be found? And what do Redditors think about biotech? We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we check in with our colleague Helen Branswell for her view on the current state of the Covid-19 pandemic and the ongoing vaccine rollout. Then, we're joined by David Fajgenbaum, a physician and scientist at the University of Pennsylvania, to talk about his work to identify and develop treatments for people with Covid-19. Lastly, we embark on a lightning round, covering Gilead Sciences' latest setback, a schism in Alzheimer's disease research, and a preview of the newest podcast from STAT.
34 minutes | 22 days ago
Episode 146: Paul Offit on vaccine data, 23andMe is going public, & Merck's CEO is retiring
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we recap a busy week of news, featuring 23andMe's move to go public through a blank-check company, Merck CEO Ken Frazier's retirement after three decades at the drug maker, and how the future of Biogen’s Alzheimer’s disease drug got a little more complicated. Then, Paul Offit, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, joins us to weigh in on the bounty of recent Covid-19 vaccine data from Johnson & Johnson, Novavax, and AstraZeneca. Finally, STAT's Casey Ross calls in to discuss his investigation into the FDA's chaotic approach to approving medical products that use artificial intelligence.
34 minutes | a month ago
Episode 145: Kevin Davies on the CRISPR boom, & Megan Ranney on scientific misinformation
First, we discuss the implications of Johnson & Johnson’s any-day-now data on a one-shot vaccine for Covid-19. Then, Kevin Davies, executive editor of the CRISPR Journal, joins us to talk about the strange boom in genome editing stocks and the future of the revolutionary technology. Finally, we talk to Megan Ranney, an emergency room physician and Brown University professor, about the challenges of Covid-19 science communication in a post-Trump world.
40 minutes | a month ago
Episode 144: Remembering STAT's Sharon Begley
We're spending this entire episode remembering Sharon Begley, our revered and beloved colleague who died last week from complications of lung cancer. First, STAT's Eric Boodman joins us to discuss Sharon's path-breaking career and what he learned from reporting out her obituary. Then, a trio of STAT editors call in to talk about what it was like to work with Sharon, and we hear from number of her colleagues about what made her a singular writer, mentor, officemate, and friend.
30 minutes | a month ago
Episode 143: #JPM21: Déjà vu in Alzheimer's research, and OWS's legacy
We're devoting this episode to the news coming out of the just-concluded J.P. Morgan Healthcare Conference, the drug industry's largest annual meeting. First, we'll dissect Eli Lilly's surprising data on a new Alzheimer's disease treatment and dig into its implications for the field. Then, we discuss whether there's a bubble inflating in the genome editing world, debate who will run the FDA under a President Biden, and consider the legacy of Moncef Slaoui, the outgoing leader of Operation Warp Speed.
29 minutes | 2 months ago
Episode 142: Bob Nelsen on the pandemic's next phase, plus Biden's biopharma plans & a CES preview
On this year's first episode, STAT Washington correspondent Lev Facher joins us to break down the implications of a Democrat-controlled Senate. Then, our colleague Erin Brodwin calls in to talk about CES, the massive tech conference taking place next week. Finally, we chat with Bob Nelsen, a biotech venture capitalist and one of the few people who saw the coming pandemic with clarity months before everyone else, about what's ahead in 2021.
35 minutes | 2 months ago
Episode 141: Moderna's vaccine milestone, Warp Speed's hurdles, and biotech in 2021
It's the final episode of 2020. We dig into the second vaccine that's been recommended by a panel of FDA advisors, and look ahead to see what's in store for biotech in 2021.
34 minutes | 2 months ago
Episode 140: Pfizer's Covid-19 vaccine — the debate, details, and distribution
Are Covid-19 vaccines safe for teens? Is the U.S. taking too long to authorize one? And how do you prepare for an FDA grilling?
29 minutes | 3 months ago
Episode 139: Angela Rasmussen on AstraZeneca's confusing data, & Adam Koppel on biotech in 2021
Can too much Covid-19 vaccine be a bad thing? Is biotech in a bubble? And how do you make blind mice see again?
23 minutes | 3 months ago
Episode 138: The latest Covid-19 vaccine, Biden's pandemic plans, and Bill Gates unfiltered
How do we measure whether Covid-19 vaccines work? What does Joe Biden think of the drug industry? And does Anthony Fauci think about retirement?
29 minutes | 3 months ago
Episode 137: Natalie Dean on Pfizer's Covid-19 vaccine, plus the FDA's Alzheimer's quandary
How well does Pfizer's Covid-19 vaccine work? What's the difference between efficacy and effectiveness? And should the FDA approve Biogen's Alzheimer's drug?
27 minutes | 4 months ago
Bracing for a pandemic winter, Biogen's fortune at the FDA, and remembering a remarkable 12-year-old
How bad will this winter be? Is everything coming up Biogen? And who's going to be president on Jan. 20? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. First, STAT's Helen Branswell joins us to discuss what the winter has in store for the ongoing Covid-19 pandemic. Then, we discuss the latest surprising twist in Biogen’s quest to win FDA approval for a polarizing treatment for Alzheimer’s disease. Finally, STAT reporter Casey Ross joins to talk about the recent death and legacy of Bertrand Might, a 12-year boy born with a rare genetic disease.
30 minutes | 4 months ago
Episode 135: Pfizer's Covid-19 mystery, Ashish Jha on pandemic response, & STAT turns 5
When are we getting Covid-19 vaccine data? Will concerts ever be safe again? And what's a "Bionomy"?
25 minutes | 4 months ago
Episode 134: Erik Gordon on SPACs, plus Covid-19 vaccines, & Biogen's case in Alzheimer's
Who's voice rings loudest at the FDA? Is it wise to give hedge funds a blank check? And how will the Biogen saga end?
28 minutes | 4 months ago
Episode 133: A week of pauses, pharma’s statehouse spending, & how HBCUs approach Covid-19 trials
Is your local lawmaker flush with pharma cash? How does racism in medicine loom over Covid-19 studies? And who decides when a clinical trial goes on pause?
23 minutes | 5 months ago
Episode 132: How Trump's case of Covid-19 affects biotech, medicine, and the FDA with George Scangos
Why is the president making drug ads? Are antibodies the new vaccines? And is it ethical for doctors to talk about President Trump's health?
25 minutes | 5 months ago
Episode 131: Saad Omer on Covid-19 vaccine trials, & Ethan Weiss on intermittent fasting
Can an itchy arm ruin a clinical trial? Does intermittent fasting work? And is pharma more trustworthy than the CDC?
26 minutes | 5 months ago
Episode 130: A road map for Covid-19, the gold rush in health tech, & D.C.'s pandemic unrest
Is superspreading an Olympic event? Will Covid-19 forever change health tech? And what are the limits of Anthony Fauci's patience?
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2020